

Mineralocorticoid receptor antagonists no benefit post MI

April 19 2016



(HealthDay)—For patients with post-myocardial infarction (MI) heart

failure, mineralocorticoid receptor antagonists (MRAs) do not improve outcome, according to a study published in the April 26 issue of the *Journal of the American College of Cardiology*.

Farzin Beygui, M.D., Ph.D., from the Centre Hospitalier Universitaire de Caen in France, and colleagues randomized 1,603 patients to receive either an MRA regimen with a single intravenous bolus of potassium canrenoate followed by oral spironolactone for six months in addition to standard therapy or to standard therapy alone. At six-month follow-up, the primary outcome was a composite of death, resuscitated cardiac arrest, significant ventricular arrhythmia, indication for implantable defibrillator, or new or worsening [heart failure](#).

The researchers found that the primary outcome occurred in 11.8 percent of patients in the treatment group and 12.2 percent in the control group (hazard ratio, 0.97; 95 percent confidence interval [CI], 0.73 to 1.28), while death occurred in 1.4 and 2.1 percent, respectively (hazard ratio, 0.65; 95 percent CI, 0.30 to 1.38). The odds of [death](#) were decreased in the treatment group in a non-pre-specified exploratory analysis (0.5 versus 2.4 percent; hazard ratio, 0.20; 95 percent CI, 0.06 to 0.70) in the subgroup of ST-segment elevation MI (1,229 patients), but not in non-ST-segment elevation MI.

"The study failed to show the benefit of early MRA use in addition to standard therapy in [patients](#) admitted for MI," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical devices industries.

More information: [Full Text \(subscription or payment may be required\)](#)
[Editorial \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Mineralocorticoid receptor antagonists no benefit post MI (2016, April 19) retrieved 4 May 2023 from <https://medicalxpress.com/news/2016-04-mineralocorticoid-receptor-antagonists-benefit-mi.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.